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Abstract: Reprogramming of somatic cells has great potential to provide therapeutic 
treatments for a number of diseases as well as provide insight into mechanisms underlying 
early embryonic development. Improvement of induced Pluripotent Stem Cells (iPSCs) 
generation through mRNA-based methods is currently an area of intense research. This 
approach provides a number of advantages over previously used methods such as DNA 
integration and insertional mutagenesis. Using transfection of specifically synthesized 
mRNAs of various pluripotency factors, we generated iPSCs from mouse embryonic 
fibroblast (MEF) cells. The genetic, epigenetic and functional properties of the iPSCs were 
evaluated at different times during the reprogramming process. We successfully introduced 
synthesized mRNAs, which localized correctly inside the cells and exhibited efficient  
and stable translation into proteins. Our work demonstrated a robust up-regulation  
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and a gradual promoter de-methylation of the pluripotency markers, including non-transfected 
factors such as Nanog, SSEA-1 (stage-specific embryonic antigen 1) and Rex-1 (ZFP-42, 
zinc finger protein 42). Using embryonic stem cells (ESCs) conditions to culture the iPS 
cells resulted in formation of ES-like colonies after approximately 12 days with only  
five daily repeated transfections. The colonies were positive for alkaline phosphatase  
and pluripotency-specific markers associated with ESCs. This study revealed the ability  
of pluripotency induction and generation of mouse mRNA induced pluripotent stem cells 
(mRNA iPSCs) using transfection of specifically synthesized mRNAs of various pluripotency 
factors into mouse embryonic fibroblast (MEF) cells. These generated iPSCs exhibited 
molecular and functional properties similar to ESCs, which indicate that this method  
is an efficient and viable alternative to ESCs and can be used for further biological, 
developmental and therapeutic investigations. 
Keywords: pluripotency; reprogramming; epigenetics; induced pluripotent stem cells;  
in vitro transcription 
 
1. Introduction 
Great advances have been rapidly achieved in reprogramming of somatic cells to generate cells with 
greater pluripotency that aid in understanding the mechanisms of both differentiation and dedifferentiation. 
Numerous methods have been used for somatic cell reprogramming especially to the pluripotent state, 
which has been successfully achieved through transferring somatic cell nuclear material into oocytes 
(SCNT) [1–3] and through creation of cell hybrids by fusion of somatic cells with pluripotent cells [4–6]. 
In addition, reprogramming can be attained via exposing somatic cells directly to extracts of oocytes [7], 
embryonic germ cells [8], embryonic carcinoma cells or embryonic stem cells (ESCs) [9]. Although, 
there are significant technical and ethical challenges associated with the previously mentioned 
methods, it is clear that the cytoplasm of oocytes or pluripotent cells contain multiple factors responsible  
for reprogramming of somatic cells [1,10]. Recent stem cell genomic research generated induced 
pluripotent stem cells (iPSCs), suggesting that reprogramming of somatic cells can be achieved 
through ectopic expression of defined specific transcription factors (TFs) [11–13]. Utilization of iPSCs 
in science and medicine in place of ESCs eliminates the controversy of embryo utilization to derive 
stem cells, thereby overcoming the challenges of using non-ethical sources. iPSCs are produced  
by somatic cell reprogramming and are very similar to natural ESCs, showing the capacity to 
differentiate into numerous cell types and with the ability to self-renew. The possibility to derive iPSCs from 
a patient’s own cells also avoids the risk of immunologic rejection [13]. Moreover, it has possible broad 
application to solve problems in tissue engineering, regenerative medicine, cell replacement therapy 
and drug development. Since the initial generation of iPSCs from mouse embryonic fibroblast (MEF) 
cells by Takahashi and Yamanaka (2006) [11], there have been numerous refinements of this method  
as the potential therapeutic application of iPS cell lines generated by DNA-based approaches has  
been hampered by its modification of the host genome through the integration of DNA sequences  
that may cause mutations and/or activation of proto-oncogenes expression leading to malignancy  
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and undesired results [13–20]. In spite of avoiding use of integrating viral vectors [11,21–26] and 
using the non-integrative DNA-based approaches including non-integrating viral vectors as adenovirus  
and sendai virus [27,28] or using virus-free approaches such as plasmids, minicircles and episomal  
vectors [14,15,29–32], the integration problem of DNA is difficult to be completely excluded. Therefore, 
discovery of more suitable ways for pluripotency induction without incurring genetic changes (i.e., DNA-free 
methods) has become the focus of intense research efforts. 
iPSCs have been derived through protein transduction of recombinant transcription factors [33,34] 
but the in vivo functional capacity of these bacteria-produced proteins may be compromised because 
essential modifications that only occur in mammalian cells may be lacking. In addition, post-translation 
modification of proteins may be a costly and low efficiency method. Also, over-expression and 
transfection of ESCs-associated microRNAs (miRNAs) were demonstrated to generate non-integrative 
human and mouse iPSCs [35–37] but a clear picture is needed of how miRNAs influence the 
pluripotent state of cells in order to render miRNA-based reprogramming an optimal and robust 
method. Recently, a safer and more efficient method for cellular reprogramming was performed 
through introduction of modified mRNA molecules encoding the reprogramming factors into somatic 
cells (mRNA-mediated gene delivery) and promoted highly efficient protein expression when used in 
hematopoietic progenitor cells, mesenchymal stromal cells, dendritic cell and lymphocytes [38–40]. 
Also, the transfected host cell undergoes a phenotypic conversion and steadily expresses the changed 
cell phenotype [41]. Using mRNA-mediated gene delivery, activated B cell and dendritic cells were 
able to express specific T lymphocyte responses when transfected with mRNAs of co-stimulatory 
molecules and viral antigens [42,43]. This method has been used to derive astrocytes from neurons; 
and fibroblasts as well as astrocytes that have been reprogrammed into cardiomyocytes [44]. This 
technique has been validated recently for human somatic cell reprogramming to generate iPSCs that 
showed successful activation of the pluripotency genes in the transfected somatic cells [45–47]. 
Warren, Mandal and their colleagues efficiently derived human iPSCs through long time exposure  
to a complex combination of modified RNA and immune suppressors [48,49]. In 2014, the derived human 
iPSCs using mRNAs under research-grade conditions were converted into a putative good manufacture 
practice (GMP) grade environment that represents a basis for the future use of human induced pluripotent 
stem cells (hiPSCs) in clinical trials [50]. 
The main goal of our research was to find suitable conditions for generation of mouse iPSCs  
by mRNA transfection of reprogramming factors into mouse somatic cells through minimum exposure 
time of transfection, to develop a model for further research, in spite of few reports concerning  
the utilization of mRNAs of reprogramming factors to induce pluripotency in murine species [51].  
The generated iPSCs will be subjected to some analyses to determine whether their properties matched 
that of pluripotent embryonic stem cells. We also aimed to check the onset of marker genes activation 
through following up their expression levels and promoter methylation changes during reprogramming. 
This research will provide the basis for a better understanding of regulation of the reprogramming 
process and aid in discovering additional mechanisms of early embryonic developmental processes. 
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2. Results 
2.1. Plasmid Construction and mRNA Synthesis 
The protocol of plasmid construction and mRNA synthesis was summarized as shown in Figure 1. 
The mammalian expression plasmid (pCDNA3) was used as a platform to prepare the mRNA of each 
transcription factor by in vitro transcription (IVT) using T7 RNA polymerase enzyme. Mouse organs 
expressing the four genes of interest (Oct4, Sox2, c-Myc and Klf4) were detected according to Mouse 
Genome Database (MGD) at the Mouse Genome Informatics website (MGI) (The Jackson Laboratory, 
Bar Harbor, Maine). Using RT-PCR, the four transcription factors were amplified from testis (Oct4  
and Sox2), small intestine (c-Myc), and colon (Klf4) using the previously mentioned protocol  
and primers (Figure 2a). The PCR products and the plasmid (pCDNA3) were purified, and then 
digested using restriction enzymes, EcoRI and XhoI (Figure 2b). The digested fragments and plasmid 
were purified, ligated to each other and then transformed into DH5α-E.coli competent bacterial cells.  
The positive clones for PCR were cultured for plasmid extraction. Extracted plasmids from positive 
colonies were single and double digested to demonstrate the correct expected fragment sizes of both 
pCDNA3 and the four genes (Figure 2c). For confirmation, the extracted recombinant plasmids were 
sent to Life Technologies Co., Ltd. (Shanghai, China) for sequencing which resulted in four specific 
fragments 1228, 960, 1320, and 1463 bp for Oct4, Sox2, c-Myc and Klf4, respectively. BLAST (Basic Local 
Alignment Search Tool) of the resulting sequences of the 4 products according to National Center for 
Biotechnology Information (NCBI, Bethesda, MD, USA) showed that each gene had a high percent of 
sequence homology to its corresponding reference sequence from mouse, as follows: 98%, 99%, 99% and 
98% for Oct4, Sox2, c-Myc and Klf4, respectively. 
Figure 1. mRNA synthesis procedures. This diagram illustrates our protocol used to in vitro 
synthesize through cloning of the Open Reading Frame (ORF) of the interested genes (a); 
digestion the eukaryotic expression vector (pCDNA3) at the desired region (b); followed 
by the ligation of the produced products (c) in which the ORF was located downstream  
to the T7 promoter region. For mRNA synthesis, the newly constructed plasmid was 
linearized (d) through single cutting by XhoI. The linear plasmid was used for mRNA 
synthesis according to the manufacturer’s protocol (e). 
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To synthesize the mRNA of the inserted transcription factors, the designed recombinant plasmids 
were linearized using XhoI, then processed according to kit directions. After purification, the concentration 
and Optic Density (OD) values of each transcription factor mRNA were measured using a NanoDrop® 
ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA) as follows; 370.26, 434.97, 
551.53, and 676.97 ng/µL for Oct4, Sox2, c-Myc, and Klf4 respectively. 
Figure 2. Plasmid construction and mRNA synthesis. (a) Successful amplification  
of the four factors from selected organs using specific primers for each. Oct4 (O) and Sox2 (S) 
were amplified from testes while c-Myc (C) was amplified from small intestine. Klf4 (K) 
was correctly amplified from colon. The DNA marker (M) used was a 2000 bp marker;  
(b) The eukaryotic expression vector (pCDNA 3) was digested using the same enzymes 
used for cutting the genes. Lane (1) shows the result of double restriction of the plasmid 
using EcoRI and XhoI, while Lane (2) revealed the single cut using XhoI. Lane (3), shows  
the uncut circular plasmid. (M): DNA marker (5000 bp); (c) Confirmation of the successful 
cloning through digestion of the newly formed recombinant plasmids (pCDNA–Oct4, 
pCDNA–Sox2, pCDNA–cMyc and pCDNA–Klf4) using EcoRI and XhoI enzymes resulted 
in two bands that were similar to the expected size of each gene as showed in Lane (2), 
while Lane (1) shows the single cut of each recombinant plasmid (M): DNA marker (5000 bp). 
 
2.2. Optimization of Transfection Conditions 
To optimize the transfection conditions, mRNA encoding green fluorescent protein (mGFP) was 
synthesized in the same manner mentioned above, and according to the lipofection protocol,  
it was transfected to MEF cells, which showed abundant expression after 24 h of transfection. More 
than 75% of the cells showed cytoplasmic localization of GFP (Figure 3). To determine the appropriate 
amount of mRNAs for transfection, the cells were transfected with different amounts of mRNA  
(1, 1.5 and 2 µg per each well), using 24-well culture plates. After 24 h, transfection efficiency was 
detected by Fluorescence Activated Cell Sorting (FACS), and we observed that the most suitable 
amount of mRNA was 1 µg per well as shown in Figure 3d. 
Next, we transfected mRNAs of the reprogramming factors into cells using equal amounts of each 
factor; 0.25 µg of each mRNA were mixed together and transfected into the cells. One day later,  
the immunocytochemistry staining confirmed the correct, predominantly intra-nuclear localization  
of the reprogramming factors (Figure 4). To further characterize the reprogramming protocol,  
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the kinetics and stability of the intracellular expressed protein after transfection was monitored by 
FACS using mRNA encoding the GFP. The results showed that protein expression could be detected 
after 6 h of transfection and reached maximum expression level at 18 h post transfection. Subsequently 
protein expression exhibited a rapid decline from 48 to 72 h, after which the lowest expression level 
persisted (Figure 5). 
Figure 3. Transfection of mouse embryonic fibroblast (MEF) with green fluorescent 
protein (GFP) mRNA. Seeded cells in one well of a 24-well plate were transfected using  
1 µg of mRNA of the green fluorescent protein according to the lipofection protocol (a,b);  
The microscopic fluorescence and bright field images (magnification 100×) of the cells 24 h 
after transfection, respectively; (c) Histogram for transfection efficiency analysis showed 
that more than 75% of the cells successfully expressed GFP after 24 h of lipofection;  
(d) Optimization of the transfected amount of mRNA revealed that 1 µg of mRNA (black 
line) achieved the highest expression value compared to 1.5 µg (green line) and 2 µg (blue line). 
 
Figure 4. Transfection of MEF with mRNA of the four transcription factors. Cells were 
transfected with 1 µg mRNA (0.25 µg of each factor) and immunostained for the  
expressed proteins of the introduced factors after 24 h, showing nuclear localization of the 
4 factors. Cellular nuclei were counter-stained by 4',6-diamidino-2-phenylindole (DAPI); 
(magnification 100×). 
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Figure 5. Kinetics and stability monitoring of the intracellular expressed proteins  
of the introduced factors. (a) Transfected cells with 1 µg of mRNA (GFP) were 
photographed under a fluorescence microscope (magnification 40×) and analyzed  
for fluorescence intensity at 6, 12, 18, 24, 48 and 72 h post transfection (green and red 
areas indicated the GFP- positive and GFP-negative cells, respectively); (b) Fluorescence 
Activated Cell Sorting (FACS) analysis revealed an increased intensity that reached  
the maximum expression at 18 h followed by decline until 72 h post transfection.  
Non-transfected MEF cells were used as a negative control. 
 
2.3. Generation of mRNA Induced Pluripotent Stem Cells (mRNA iPS) 
According to the optimized transfection conditions, 1 × 105 MEF cells were transfected with  
a mixture of 1 µg mRNA every 24 h according to the time schedule schematically illustrated in Figure 6a. 
Cells were subjected to 5 consecutive transfections followed by changing the culture conditions to that of 
ESCs. During transfection, we observed cellular morphological changes from the mesenchymal appearance 
of fibroblasts to compact, round epithelial cell morphology. These phenotypic changes increased until  
we observed small colony-like structures at day 8 of reprogramming. These colony-like structures 
increased in size and exhibited tightly defined borders and a high nuclear/cytoplasm ratio by day 15  
after the first transfection (Figures 6b and 7a). We obtained an average of 100 to 130 colonies per line  
of reprogramming with reprogramming efficiency about 0.1% to 0.13%. 
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Figure 6. Generation of induced pluripotent stem cells. (a) Diagram illustrating the 
reprogramming protocol used in our experiment; (b) The lipofected cells showed changes in 
their morphology from the fibroblast appearance to round, like that of epithelial cells, 
which gradually increased in the first 7 days until the appearance of the first small colony-like 
structure at the 8th day of culture. The colonies subsequently increased in size to form 
embryonic stem (ES)-like colonies by the 15th day post transfection; (magnification 100×). 
 
Figure 7. Characterization of the mRNA induced pluripotent stem cells (iPSCs).  
(a) The morphological characteristics of iPSCs with round ES-like colonies were distinguished 
by tightly defined borders and a high nuclear/cytoplasm ratio (magnification 40×);  
(b–d) showed positive alkaline phosphatase activity of the mRNA iPS either grossly  
(b, magnification 10×) or through microscopic observation (c, magnification 100×)  
and (d, magnification 200×); (e) Total RNA was isolated from three mRNA iPS clones  
and non-transfected MEF cells were used for RT-PCR to detect expression of pluripotency 
markers: Oct4, Sox2, Nanog, Rex1, Klf4 and cMyc. Results showed that iPS colonies 
expressed all markers in contrast to MEF cells; (f) Detection of the methylation status  
of Nanog and Oct4 promoters in both MEF cells, iPS and ESCs by bisulfite sequencing revealed 
a high percentage of de-methylation in both promoters compared to the parent MEF cells. Open 
circles indicate the un-methylated state and dark, filled circles indicate the methylated state. 
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Figure 7. Cont. 
 
 
2.4. Characterization and Identification of the Generated mRNA iPSCs 
The generated mRNA induced pluripotent stem cells (iPSCs) colonies were subjected to a number  
of molecular and functional assays to assess pluripotency. The colonies were positive for alkaline 
phosphatase activity (ALP) (Figure 7b–d). The derived iPSCs colonies were stained for pluripotency 
proteins and were positive for Oct4, Sox2, Nanog, SSEA-1, Klf4, and c-MYC, while untreated cell 
populations were negative for these factors (Figure 8). To assure the pluripotency gene expression  
in the mRNA iPS cells, RT-PCR was conducted using fibroblast cells. The results demonstrated robust 
expression of pluripotency associated factors, OCT4, Nanog, Rex-1, c-Myc, and Klf4, compared  
to donor fibroblasts (Figure 7e). To confirm successful genomic reprogramming, the methylation 
patterns of mouse Oct4 and Nanog gene promoter regions were analyzed in both the generated iPS 
clones and in the parental MEFs using the bisulfite conversion method mentioned above. Sequence 
analysis of the cloned promoter region revealed extensive de-methylation of the majority of analyzed  
Cytosine-phosphate-Guanine sites (CpGs) in iPSCs clones, while they remained methylated in MEF 
cells (Figure 7f). The developmental potential of the derived iPS was tested by determining its ability 
for in vitro differentiation. Embryoid bodies (EBs) were successfully formed and showed high 
expression of the specific markers for each of the three primary developmental germ layers using  
RT-PCR for detection of ectodermal markers (Nestin and Sox1), mesodermal markers (Smooth Muscle 
Aactin (SMA) and Brachyury) and endodermal markers (Sox17 and Alpha feto protein (AFP)). 
Moreover, the results revealed lower expression of stem cell markers, including Oct4 and Sox2 (Figure 9a–c). 
The in vitro differentiation revealed also positive immune-staining for the specific markers of the  
three germ layers; βIII tubulin for ectoderm, smooth muscle actin (SMA) for mesoderm and Sox17  
for endoderm (Figure 9d). To verify that the derived iPSCs had acquired pluripotency, they were 
subcutaneously injected into Severe Combined Immune deficient (SCID) mice and shown to form tumors 
after six weeks. Histological analysis revealed teratomas comprised of tissues of all three germ layers 
including cartilage, muscle, fat (mesoderm), pigmented epidermal tissue (ectoderm), and epithelium 
(endoderm) (Figure 9e). Karyotyping analysis of the iPS clones showed the normal karyotype  
and chromosome numbers of the murine species. 
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Figure 8. Immunofluorescence identification of the generated iPS. The newly derived 
mRNA iPS colonies were stained for the specialized markers of pluripotency: Oct4,  
Sox2, Nanog, SSEA-1, Klf4 and c-Myc. Nuclei were counter-stained with DAPI;  
(magnification 200×). 
 
 
Figure 9. Pluripotency of the generated mRNA iPS from mouse MEF cells.  
(a,b) Assess pluripotency of the derived iPSCs; the cells were induced to form  
embryoid bodies (EB). The EB morphology in suspension culture (a, magnification 40×)  
(b, magnification 100×); (c) Comparative gene expression profiles of iPSCs and EB, using 
RT-PCR and showing that levels of pluripotent stem cell markers (Oct4, Sox2) decreased  
in EB while ectodermal markers (Sox1, Nestin), mesodermal markers (smooth muscle actin 
(SMA), brachyury) and endodermal markers (Sox17, AFP) were highly expressed in EB cells; 
(d) Immuno-staining confirming in vitro differentiation into three germ layers; βIII tubulin 
(ectodermal), SMA (mesodermal), and Sox17 (endodermal). Secondary antibodies were 
labeled with Alexa 488 (green, 40×) and Cy3 (red, 100×); (e) Hematoxylin and eosin 
staining of teratoma sections generated from mRNA iPSCs; (i) pigmented epithelium 
(ectoderm); (ii) epidermal tissue (ectoderm); (iii) cartilage like structure, fat and muscle 
tissues (mesoderm); (iv) epithelium (endoderm) 100×; (f) normal karyotyping and chromosomes 
numbers of mRNA iPSCs. 
 
Int. J. Mol. Sci. 2014, 15 21850 
 
 
Figure 9. Cont. 
 
2.5. Genetic and Epigenetic Changes of the Reprogramming Factors and Pluripotency Markers during 
mRNA iPS Generation 
The total and endogenous expression levels of the pluripotency genes including the reprogramming 
factors were quantified using the real time PCR at different times (D1, D6, D9, D12, and D15) during 
iPSCs generation. All transfected factors (Oct-4, Sox2, c-Myc and Klf4) were highly expressed after  
the first transfection while the non-transfected factors (Nanog and Rex-1) showed modestly increased 
expression. This period was followed by a robust increase in all factors’ quantities after the last 
transfection (D6). After that, expression levels of all factors decreased at D9 and D12 of reprogramming. 
At D15, pluripotency factor expression level increased (Figure 10a,b). To confirm the expression  
of non-transfected factors, cells were fixed after the last transfection and stained for Nanog and SSEA-1. 
Immunofluorescence analysis confirmed nuclear localization of Nanog and cell surface localization  
of SSEA-1 (Figure 10c). To detect the changes in the epigenetic status of the transfected cells, 
methylation patterns of the promoter regions were analyzed at different intervals of transfection  
(D1, D6, D9, D12 and D15). Gradual increases in de-methylation of Oct4 and Nanog loci from D1  
to D15 of reprogramming were observed. We observed that the percentage of non-methylation  
of the Nanog promoter changed from 20% at D0 to about 80% at D15 of the reprogramming time.  
The same changes were detected for the Oct4 promoter, which revealed 70% un-methylation at D15  
in contrast to the low percent (about 18%) prior to transfection (Figure 11). 
Figure 10. Changes in introduced factors and pluripotency markers during reprogramming. 
Quantification of pluripotency factors expression by qRT-PCR at different times (D1, D6, 
D9, D12 and D15) throughout the reprogramming timeline. (a) Total and endogenous 
expression levels of the transfected factors; Oct4, Sox2, c-Myc and Klf4; (b) the expression 
level of non-transfected factors (Nanog and Rex-1); (c) Immunostaining of non-transfected 
factors at day 6 confirmed the results of the qRT-PCR concerning Nanog and SSEA-1,  
as they showed nuclear localization of Nanog and surface expression of SSEA-1. Nuclei 
were counterstained with DAPI; (magnification 100×). 
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Figure 11. Epigenetic modification of the Nanog and Oct4 promoters during the mRNA 
iPS generation. Methylation status of CpGs islands (columns) were analyzed from 10 
randomly sequenced clones (rows) in the promoter region of Nanog (a) and Oct4 (b) genes 
at different stages during reprogramming (D3, D6, D9, D12 and D15); Un-transfected 
MEF cells were used as control. Open circles indicate the un-methylated state and dark and 
filled circles indicate the methylated state; (c,d) The overall pattern and global analysis of 
the tested loci of Nanog and Oct4 promoters, respectively. 
a
 
b
 
3. Discussion 
mRNA based gene delivery technology in cellular reprogramming provides new opportunities  
for biomedical research and clinical application. It can offer several advantages as a safe and highly 
efficient alternative to DNA-based and protein-mediated cellular reprogramming [52], and presents 
significant promise for use in clinical trials [53] as several studies have reported its use for 
immunotherapeutic purposes [54–56]. This technique completely eliminates genome manipulation and 
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the DNA integration that may cause mutations and activation of proto-oncogenes expression, leading 
to possible malignancy and other undesired results. Several gene therapy applications prefer the use of 
mRNA instead of plasmid DNA and viral vectors in the face of its requirement for stable transgene 
expression [57]. mRNA reprogramming also surpasses obstacles in the protein delivery method 
including cost and time. mRNAs are directly translated into functional proteins in the cytoplasm with 
proper mammalian post-translational modifications; this results in greater functional efficiency when 
compared to the recombinant proteins produced in bacteria. 
In our research using synthesis and preparation of mouse specific mRNA encoding reprogramming 
factors, we established efficient plasmids that could be used in a convenient manner for in vitro 
transcription and transfection. The amplified cDNAs of these factors were cloned in an expression 
vector (pCDNA3) downstream to the T7 promoter region. Our findings revealed sufficient 
establishment of the desired plasmids based on digestion results of the newly constructed vectors.  
The in vitro transcription reaction was incorporated with synthetic cap analog and also provided with 
poly (A) tailing reagents to promote efficient transfer of RNA in the cytoplasm in accordance  
to Yisraeli and Melton (1989) [58]. As it is known that exogenous single-stranded RNA (ssRNA) 
activates antiviral defenses in human cells [59–63], the immunogenic profile of synthetic RNA need  
to be reduced to allow repeated introduction of mRNAs in the target cells for a period of time long 
enough to induce reprogramming [48,64,65]. However, the probability of this immunogenic problem  
is not that pronounced in murine cells as mentioned by Tavernier (2012) [51] who showed successful 
onset of the reprogramming process in murine cells without any measure taken to suppress the innate 
immune response. 
In this study, mRNAs of the transcription factors Oct4, Sox2, Klf4 and c-Myc (OSKM) were 
successfully transfected into MEF cells with high expression level, in contrast to the low transfection 
efficiency and high cell mortality associated with use of plasmid DNA [45,66]. In addition, all factors 
were translated into their corresponding proteins that were properly localized in the nucleus of  
the transfected cells. This is the key exigency to perform its biological activity role in cellular 
reprogramming. Protein expression levels (Enhanced Green fluorescent Protein (EGFP) as indicator) 
were sustained for several days but then sharply decreased due to degradation of the transfected 
mRNA. Therefore, several repeated transfections of mRNA were required to preserve high levels  
of protein expression for prolonged time, which is necessary for cell reprogramming, in agreement 
with observations of Warren (2010) [48] and Jin (2011) [67]. To accomplish this, we used the cationic 
vehicle method for mRNA transfection as this facilitates its uptake from repeated transfections  
in concordance with the high reprogramming efficiency of Warren (2010) [48] and in comparison  
to the low efficiency resulting from electroporation [45,47]. Taking into account the cytotoxic effect  
of lipofectamine (LF), we minimized the exposure period to LF to as little as possible. With respect  
to pluripotency induction, our results demonstrated gradual cellular phenotypic changes similar to those 
observed by Chan (2009) [68] and Smith (2010) [69], which indicate the obvious roles of these 
transcription factors during stages of cell switching. We observed, during reprogramming, that  
the expression status of the embryonic stem cell genes passed through three stages. First, we observed 
potent up-regulation of the transferred factors (OSKM) during the transfection period presumably  
due to its proper expression and to stimulatory effects during activation of the endogenous factors. This  
was confirmed by up-regulation of the non-transfected pluripotency factors, Nanog, Rex1 and SSEA-1, 
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which was consistent with the study of Yakubov (2010) [46] that reprogrammed the human fibroblasts. Loss 
of external stimuli due to stopping transfection resulted in a period of down-regulation for all these 
factors. Our findings in these two stages are similar to the findings of Plews and colleagues (2010) [45] 
who observed up-regulation of expression at day three and then decreased at day seven after cell 
electroporation. Also, Tavernier (2012) observed high expression levels of both transfected factors  
and pluripotency genes after only one transfection, which then significantly decreased in expression 
with increasing the time interval between consecutive transfections [51]. Our study revealed a third 
stage that represented a second up-regulation phase which suspected to be resulted from the activated 
endogenous genes of these factors at a time when most of the transferred factors were degraded.  
It was clear that our protocol has the ability to reactivate the inactive pluripotency genes, which  
was due to progressive de-methylation of promoter regions, resulting in turning on these factors.  
DNA methylation is considered to be a critical barrier to cellular reprogramming, so de-methylation  
at the promoter loci of pluripotency genes is a key epigenetic modification required for reprogramming,  
as mentioned by Simonsson (2004) [70]. This activation was accompanied by cell behavior alterations  
and produced small mouse ES-like colonies at D8, which was faster than obtained using DNA [11]. 
This may be attributed to the long time taken to transcribe the DNA in the nucleus, while mRNA  
was directly translated in cytoplasm. 
The majority of the generated mRNA iPS colonies showed the same morphological characteristics  
of ESCs and expression of the typical pluripotency markers besides acquiring of characteristic 
pluripotency gene expression including Oct4, Sox2, Klf4, c-MYc, SSEA-1, Rex1 and Nanog;  
in addition to positive alkaline phosphatase (ALP) activity and its tri-lineage differentiation ability  
in vitro and teratoma formation in vivo. We also observed some extent of similarity to the methylation 
profile of the promoter regions of the key pluripotency genes. This acquisition of morphological  
and molecular properties of ESCs suggested that the synthesized mRNA-derived iPS clones were 
successfully reprogrammed. 
The genomic integration approaches enable the stable expression of the factor genes in the host 
genome that explain their high iPSCs reprogramming efficiency. On the other hand, the previously 
applied non-integrating methods showed low reprogramming efficiency, ranging from 0.001% for  
the plasmids, minicircle DNAs, episomes and proteins delivery method to 0.1%–1% for the excisable 
vectors [71,72]. The mRNA-mediated gene delivery method achieved higher conversion efficiency  
in human [48], while in murine species, Tavernier and co-workers [51] succeeded only to activate  
the pluripotency genes in the transfected cells, without any detail about characterization of the colonies 
and efficiency of reprogramming. However, our study demonstrated the generation of iPSCs through 
only five consecutive transfections with moderate efficiency (about 0.1% to 0.13%) in comparison  
to the other non-integrating methods. We continue now to try multiple lines of reprogramming  
to achieve higher efficiency. 
It was observed, in this study, that most of the transfected cells expressed pluripotency markers that 
were not part of the reprogramming cocktail (Nanog, SSEA1 and Rex1) at day 6, which confirmed  
the early stages of reprogramming into iPSCs [73]. Therefore, we will go on to study the effect  
of different culture conditions and small molecules on the maintenance of iPSCs to improve the final 
reprogramming efficiency and to further analyze molecular and functional properties of the generated 
mouse mRNA iPS. 
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4. Materials and Methods 
4.1. RNA Extraction and cDNA Amplification 
Total RNA was extracted using TRIZOL® reagent (15596-026, Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. RNA quantification was performed using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 1 µg of isolated RNA was reverse 
transcribed to its corresponding cDNA using PrimeScript™ RT reagent Kit (Perfect Real Time, 
DRR037A, Takara, Dalian, China) according to the manufacturer’s protocol. 
4.2. Plasmid Construction 
The Open reading frames of Oct4, Sox2, Klf4 and c-Myc (OSKC) factors were amplified by PCR 
using PrimeSTAR® Max DNA Polymerase (DR045A, Takara, Dalian, China) and primers sets (Table 1) 
in which the cutting sequences of EcoRI and XhoI enzymes were added to the 5' end of the forward and 
reverse primers respectively. The primers were synthesized by Life Technologies Co., Ltd. (Shanghai, 
China). The produced amplicons as well as the used expression vector (pCDNA3) were digested by EcoRI 
and XhoI then purified using an universal DNA purification kit (DP214, TIANGEN, Beijing, China)  
and finally ligated to each other using T4 DNA ligase enzyme (2011A, Takara, Dalian, China) according  
to the manufacturer’s protocol. The newly formed recombinant plasmids were cloned in DH5α-E. coli 
competent cells and re-extracted using TIAN prep Mini plasmid Kit (DP103, TIANGEN, Beijing, China). 
Table 1. Primers used for amplification of the genes of interest. The restriction sites  
were underlined. EcoRI and XhoI restriction sites were used in forward and reverse  
primers, respectively. The underlined areas are the restriction sites of the used enzymes  
and the bolded are the protective nucleotides. 
Gene Accession No. ORF Primers 
Oct4 NM_013633 F: 5'CGGAATTCCGCCACCTTCCCCATGGCTGGACACC3'  
R: 5'CCCTCGAGGGTGATCAACAGCATCACTGAGCTTC3' 
Sox2 NM_011443 F: 5'CGGAATTCCGATGTATAACATGATGGAGACGGAGCT3'  
R: 5'CCCTCGAGGGTCACATGTGCGACAGGGGCAGT3' 
c-Myc NM_001177352 F: 5'CGGAATTCCGATGCCCCTCAACGTGAACTTCACC3'  
R: 5'CCCTCGAGGGTTATGCACCAGAGTTTCGAAGC3' 
Klf4 NM_010637 F: 5'CGGAATTCCGATGAGGCAGCCACCTGGCGAGT3'  
R: 5'CCCTCGAGGGCTACGTGGGATTTAAAAGTGCCTC3' 
4.3. In Vitro Transcription of mRNA 
To synthesize the mRNA of the inserted transcription factors (TFs), the designed recombinant 
plasmids were linearized by XhoI, followed by in vitro RNA transcription (IVT) using the 
mMESSAGE mMACHINE T7 kit (AM1345, Ambion®, Grand Island, NY, USA) that allows 5' cap 
and poly (A) tail formation. The transcribed mRNA was then purified using MEGAclear™ Kit 
(AM1908, Ambion®, Grand Island, NY, USA) according to the protocol of the manufacturer. The 
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mRNA concentration was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). 
4.4. Mouse Embryonic Fibroblast (MEF) Isolation 
Procedures involving animals and their care conformed to the U.S. National Institute of Health 
guidelines (NIH Pub. No. 85-23, revised 1996) and all animal experiments were reviewed  
and approved by the Institutional Animal Care and Use Committee of School of animal Science  
and Technology, Yangzhou University and performed in accordance with the Regulations  
for the Administration of Affairs Concerning Experimental Animals (China, 1988) and the Standards 
for the administration of experimental practices (Jiangsu, China, 2008). Uterine horns from pregnant 
female mice (C57/BL) at 13 days post-coitum (d.p.c) were removed, washed with phosphate-buffered 
saline (PBS) and opened. Each embryo was separated from its placenta and surrounding membranes 
then the head and viscera were removed from the isolated embryos. The remaining parts were washed 
in PBS, minced using a pair of scissors until the pieces were able to be pipetted, then suspended  
in 0.25% Trypsin/ EDTA (Gibco®, Grand Island, NY, USA) solution (1–2 mL per embryo) and 
incubated at 37 °C for 15 min with gentle shaking. After trypsinization, an equal amount of MEF 
medium was added and pipetted up and down several times to dissociate the cells. The tissue/medium 
mixture was filtered to remove the remaining pieces of tissue, then the cells were collected  
by centrifugation (1000 rpm for 7 min) and resuspended in fresh medium. 106 cells were cultured  
on 100 mm dishes at 37 °C with 5% CO2 (this is “passage No. 0”). We used MEFs within three passages 
to avoid replicative senescence. 
4.5. Cell Culture 
Mouse Embryonic fibroblasts (MEF) were cultured on gelatin coated dishes with MEF growth 
media containing high glucose Dulbecco’s Modified Eagle’s (DMEM) medium (CORNING, Corning, 
NY, USA) 10% FBS (Hyclone, South Logan, Utah, USA), 4 mM L-glutamine (25030-081, Gibco®, 
Grand Island, NY, USA) and 1:100 penicillin–streptomycin. After transfection, the transfected MEF 
cells and the generated iPSCs were maintained on a feeder layer of mitomycin-C inactivated MEF cells 
with mouse iPS/ES media containing DMEM (Gibco®, Grand Island, NY, USA), supplemented with  
1000 U/mL Leukemia inhibitory factor (LIF, Sigma, St. Louis, MO, USA), 15% FBS (Hyclone,  
South Logan, UT, USA), 2 mM L-Glutamine (25030-08, Gibco®, Grand Island, NY, USA), 1 × 10−4 M 
non-essential amino acids (M7145, Sigma, St. Louis, MO, USA), 1 × 10−4 M 2-mercaptoethanol 
(MB0338, Bio Basic Inc., Amherst, NY, USA) and 1% penicillin and streptomycin. 
4.6. Cell Transfection 
Before transfection, the media was changed to prepared fresh media. RNA transfection was carried 
out through cationic lipid delivery vehicles using TransIT®–mRNA Transfection Kit (MIR2225, Mirus 
Bio, Madison, WI, USA). A total 1 µg of mRNA (0.25 µg of each transcription factor) was diluted  
in 100 µL of Opti-MEM followed by addition of 2 µL BOOST reagent and 2 µL TransIT®–mRNA.  
The complex was mixed gently, incubated at RT for (2–5 min), and then introduced to culture media. 
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RNA transfection was performed in normal MEF media (DMEM + 10% FBS with antibiotic). The 
medium was changed 12 h after transfection to new media that did not contain transfection reagents. 
4.7. Quantitative Real-Time PCR (qPCR) 
The cDNA samples were analyzed by Real-Time PCR in a 7500 Real-Time PCR system (ABI, 
Carlsbad, CA, USA) using SYBR Premix Ex Taq™ (tli RNaseh Plus, RR420A, TAKRA, Dalian, 
China). Primer sequences are listed in Table 2. Relative quantification was calculated with 2−ΔΔCt  
and normalized to Gapdh. Data were presented as levels related to the expression level in MEF cells. 
Table 2. Primers used for quantitative real time PCR (qPCR). 
Gene Forward Primer Reverse Primer References 
Oct4 
Total 
5'CAGACCACCATCTGTCG
CTTC3' 
5'AGACTCCACCTCACACGG
TTCTC3' 
This study 
Endogenous 
5'TCTTTCCACCAGGCCCC
CGGCTC3' 
5'TGCGGGCGGACATGGGG
AGATCC3' 
[11] 
Sox2 
Total 
5'GGTTACCTCTTCCTCCC
ACTCCAG3' 
5'TCACATGTGCGACAGGGG
CAG3' 
Endogenous 
5'TAGAGCTAGACTCCGGG
CGATGA3' 
5'TTGCCTTAAACAAGACCA
CGAAA3' 
c-Myc 
Total 
5'CCTAGTGCTGCATGAGG
AGACAC3' 
5'TCCACAGACACCACATCA
ATTTCTT3' 
This study 
Endogenous 
5'TGACCTAACTCGAGGAG
GAGCTGGAATC3' 
5'AAGTTTGAGGCAGTTAAA
ATTATGGCTGAAGC3' 
[11] 
Klf4 
Total 
5'ACAGCCACCCACACTTG
TGACTA3' 
5'GGCGAATTTCCACCCACA
G3' 
This study 
Endogenous 
5'GCGAACTCACACAGGCG
AGAAACC3' 
5'TCGCTTCCTCTTCCTCCGA
CACA3' 
[11] 
Gapdh – 
5'TGTGTCCGTCGTGGATC
TGA3' 
5'TTGCTGTTGAAGTCGCAG
GAG3' 
This study 
4.8. Immunofluorescence 
The cells were rinsed briefly with phosphate-buffered saline (PBS) and fixed for 20 min in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at room temperature. The cells were 
permeabilized for 10 min with 0.1% Triton X-100 in PBS, and blocked for 45–60 min with 4% bovine 
serum albumin in PBS at room temperature. Cells were incubated overnight at 4 °C with one of  
the following antibodies: anti-Oct4 (1:500; Abcam, Cambridge, MA, USA), anti-Sox2 (1:500;  
NB110-37235, Novus Biologicals, Littleton, CO, USA), anti-Nanog (1:500; Abcam, Cambridge, MA, USA), 
anti-c-Myc (1:250; bs-4963R, Bioss, Woburn, MA, USA), anti-Klf4 (1:250, bs-1064R, Bioss, Woburn, MA, 
USA). This was followed by incubation with the following secondary antibody: Alexa Fluor 488-labeled  
anti-rabbit IgG (1:500; Invitrogen, Carlsbad, CA, USA). Nuclei were counterstained using DAPI (1 mg/mL 
PBS; Invitrogen, Carlsbad, CA, USA). 
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4.9. Fluorescence Activated Cell Sorting (FACS) 
To assess GFP positive cells, cultured cells washed twice with PBS after removing the culture 
media. Then the cells were detached with trypsin (0.05%, Gibco®, Grand Island, NY, USA) collected, 
centrifuged then re-suspended in PBS and were kept on ice until evaluation of GFP expression  
by a FACSAria Flowcytometer using FACSDiva software (Becton-Dickinson Immunocytometry 
Systems, BDIS, San Jose, CA, USA). 
4.10. Alkaline Phosphatase Staining 
Alkaline phosphatase (ALP) staining was performed using an AP staining kit (1101-050, SiDanSai, 
Beijing, China) according to the manufacturer’s protocol. Positive AP staining was recorded as blue  
to purple color. 
4.11. Bisulfite Genomic Sequencing 
Bisulfite treatment was performed using EZ DNA Methylation™ Kit (D5001, ZYMO RESEARCH 
CORP, Irvine, CA, USA) according to the manufacturer’s protocol. PCR primers are listed in Table 3. 
The amplified products were cloned into TOP10 (Vazyme Biotech, Nanjing, China). Ten clones were 
randomly selected, picked and sequenced with the M13 forward and M13 reverse primers for each 
gene (Invitrogen Co., Ltd., Shanghai, China). 
Table 3. Primers used for DNA methylation (bisulfite sequencing). 
Gene Forward Primer Reverse Primer 
Nanog 5'GATTTTGTAGGTGGGATTAATTGTGAATTT3' 5'ACCAAAAAAACCCACACTCATATCAATATA3' 
Oct4 
F1: 5'GTTGTTTTGTTTTGGTTTTGGATAT3'  
F2: 5'ATGGGTTGAAATATTGGGTTTATTTA3' 
5'CCACCCTCTAACCTTAACCTCTAAC3' 
4.12. In Vitro Differentiation of mRNA iPSCs 
Cells were chemically harvested by trypsinization and transferred to non-adherent bacteriological 
culture dishes in ES medium without Leukemia Inhibitory Factor (LIF) until formation of the 
aggregated cells of embryoid bodies was observed. Total RNA derived from plated embryoid bodies 
on day 6 was used for RT-PCR analysis for the three germ layer markers. The primers used for each 
germ layer are listed in Table 4. The cells were stained with anti-smooth muscle actin antibody 
(ab5694, Abcam, Cambridge, MA, USA), anti-Sox 17 antibody (cs-299, Santa Cruz, Dallas, TX, USA) 
and anti- βIII tubulin antibody (ab52901, Abcam, Cambridge, MA, USA). This was followed by 
incubation with the following secondary antibody: Alexa Fluor 488-labeled anti-rabbit IgG (A21206, 
Invitrogen, Carlsbad, CA, USA) or cy3® anti-rabbit IgG (A10520, Invitrogen, Carlsbad, CA, USA). 
Nuclei were counterstained using DAPI (1 mg/mL PBS; Invitrogen, Carlsbad, CA, USA). 
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Table 4. Primers used for detection of the three germ layers in the formed Embryoid bodies. 
Gene Accession No. Primers 
Sox1 NM_009233 F: 5'GGATCTCTGGTCAAGTCGGAG3'  
R: 5'CTGGCGCTCGGCTCTCCAGAG3' 
Nestin NM_016701 F: 5' TCTGGAAGTCAACAGAGGTGG3'  
R: 5'ACGGAGTCTTGTTCACCTGC3' 
α-SMA NM_007392 F: 5'GAGAAGAGCTACGAACTGCCTGAC3'  
R: 5'CACATCTGCTGGAAGGTAGACAG3' 
Bra NM_009309 F: 5'GTTCCTGGTGCTGGCACCCTCTGC3'  
R: 5'CAGACCAGAGACTGGGATACTG3' 
Sox17 NM_011441 F: 5'CACAGCAGAACCCAGATCTGCA3'  
R: 5'CATGTGCGGAGACATCAGCGGAG3' 
AFP NM_007423 F: 5'GTGAGCATTGCCTCCACGTGCTG3'  
R: 5'GTGACAGCCGCCAGCTGCTCCTC3' 
4.13. Teratoma Formation and Histological Analysis 
iPSCs were suspended at 1 × 107 cells/mL of DMEM containing 10% FBS. 300 µL of the cell 
suspension were injected subcutaneously in SCID immune-deficient mice which were anesthetized 
with diethyl ether. Six weeks after injection, tumors were surgically dissected, fixed in 10% neutral 
formaldehyde, and embedded in paraffin. Sections were stained with hematoxylin and eosin. 
4.14. Karyotyping Analysis 
Karyotypes were determined following the Cold Spring Harbor Protocol [74] which is an adapted 
protocol from “Detection and Analysis of Mouse Genome Alterations and Specific Sequences,”  
Chapter 12, in Manipulating the Mouse Embryo, 3rd edition, Cold Spring Harbor Laboratory Press,  
Cold Spring Harbor, NY, USA. 
5. Conclusions 
In this study, mouse mRNAs of the key four reprogramming genes were successfully synthesized 
through their cloning in the eukaryotic expression vector pCDNA3.0 and successfully transferred to 
the somatic cells with efficient translation. Our work demonstrated a gradual de-methylation of the 
pluripotency markers promoters leading to their high expression during the reprogramming process. 
Five consecutive transfections resulted in pluripotency induction in the fully differentiated cells 
converting them into iPSCs with the same morphological, biological and functional properties of 
ESCs. The newly formed ES-like colonies were positive for alkaline phosphatase, expressed ES cell 
specific markers and showed an appropriate promoter methylation pattern typical of ESCs. Therefore, 
activation of mouse pluripotency genes and induced pluripotent stem cells generation can be achieved in 
a safe manner with better efficiency when using the mouse specific synthesized mRNAs for transfection. 
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